Literature DB >> 12788655

Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line.

Taikoh Dohjima1, Nan Sook Lee, Haitang Li, Takatoshi Ohno, John J Rossi.   

Abstract

The EWS/Fli-1 fusion gene encodes an oncogenic fusion protein. The fusion is a product of the translocation t(11;22) (q24;q12), which is detected in 85% of Ewing sarcoma and primitive neuroectodermal tumor cells. Utilizing intracellularly expressed 21- to 23-nucleotide small interfering RNAs (siRNAs) targeting the EWS/Fli-1 fusion transcript in an Ewing sarcoma cell line, we achieved a greater than 80% reduction in the EWS/Fli-1 transcript. The reduction in transcript levels was accompanied by growth inhibition of an Ewing cell line. In addition to quantitating the reduction of the fusion transcript, we carefully monitored reduction of the endogenous EWS and Fli-1 mRNAs as well. One of the two siRNAs targeted to the fusion transcript also partially downregulated the Fli-1 mRNA, further potentiating the growth inhibition. These results highlight both the power of siRNAs and the potential side reactions that need to be carefully monitored. In addition, these results provide the first demonstration of expressed siRNAs downregulating an oncogenic fusion transcript. The results and observations from these studies should prove useful in targeting other fusion transcripts characteristic of sarcomas and erythroleukemias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788655     DOI: 10.1016/s1525-0016(03)00101-1

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  24 in total

1.  EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

Authors:  Alexandre Prieur; Franck Tirode; Pinchas Cohen; Olivier Delattre
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

2.  Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

Authors:  Patrick J Grohar; Girma M Woldemichael; Laurie B Griffin; Arnulfo Mendoza; Qing-Rong Chen; Choh Yeung; Duane G Currier; Sean Davis; Chand Khanna; Javed Khan; James B McMahon; Lee J Helman
Journal:  J Natl Cancer Inst       Date:  2011-06-08       Impact factor: 13.506

3.  Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms.

Authors:  Kelly A France; Jennifer L Anderson; Ann Park; Christopher T Denny
Journal:  J Biol Chem       Date:  2011-04-28       Impact factor: 5.157

4.  Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.

Authors:  Matt L Harlow; Nichole Maloney; Joseph Roland; Maria Jose Guillen Navarro; Matthew K Easton; Susan M Kitchen-Goosen; Elissa A Boguslawski; Zachary B Madaj; Ben K Johnson; Megan J Bowman; Maurizio D'Incalci; Mary E Winn; Lisa Turner; Galen Hostetter; Carlos María Galmarini; Pablo M Aviles; Patrick J Grohar
Journal:  Cancer Res       Date:  2016-10-03       Impact factor: 12.701

Review 5.  Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.

Authors:  Beatrice M Seddon; Jeremy S Whelan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.

Authors:  Günther H S Richter; Stephanie Plehm; Annette Fasan; Sabine Rössler; Rebekka Unland; Idriss M Bennani-Baiti; Marc Hotfilder; Diana Löwel; Irene von Luettichau; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Heinrich Kovar; Martin S Staege; Carsten Müller-Tidow; Stefan Burdach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

7.  Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.

Authors:  Yang Liu; Joseph M Eckenrode; Yinan Zhang; Jianjun Zhang; Reiya C Hayden; Annet Kyomuhangi; Larissa V Ponomareva; Zheng Cui; Jürgen Rohr; Oleg V Tsodikov; Steven G Van Lanen; Khaled A Shaaban; Markos Leggas; Jon S Thorson
Journal:  J Med Chem       Date:  2020-11-16       Impact factor: 7.446

8.  Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma.

Authors:  Takatoshi Yamamoto; Takatoshi Ohno; Kazuhiko Wakahara; Akihito Nagano; Gou Kawai; Mitsuru Saitou; Iori Takigami; Aya Matsuhashi; Kazunari Yamada; Katsuji Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-10       Impact factor: 4.553

9.  EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma.

Authors:  Jozef Ban; Idriss M Bennani-Baiti; Max Kauer; Karl-Ludwig Schaefer; Christopher Poremba; Gunhild Jug; Raphaela Schwentner; Oskar Smrzka; Karin Muehlbacher; Dave N T Aryee; Heinrich Kovar
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

10.  Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.

Authors:  Patrick J Grohar; Laure E Segars; Choh Yeung; Yves Pommier; Maurizio D'Incalci; Arnulfo Mendoza; Lee J Helman
Journal:  Clin Cancer Res       Date:  2013-11-25       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.